Alligator Bioscience AB announces outcome of exercise of warrants series TO 14
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.
The exercise period for warrants series TO 14 (“TO 14”)
in Alligator Bioscience AB (“Alligator Bioscience” or the “Company”) (the “Warrant Programme”), issued in connection with the Company’s rights issue of units carried out during October – December 2025 (the “Rights Issue”) ended on 19 March 2026. The outcome shows that a total of 93,589,862 TO 14 were exercised for subscription of 93,589,862 new ordinary shares, corresponding to an exercise rate of approximately 38 percent. Through the exercise of TO 14, Alligator Bioscience will receive gross proceeds of approximately SEK 19 million.
Exercise of TO 14
The exercise period for TO 14 took place during the period 5 – 19 March 2026. One (1) TO 14 entitled the holder to subscribe for one (1) new ordinary share in the Company at a subscription price of SEK 0.20 per ordinary share. The outcome shows that a total of 93,589,862 TO 14 were exercised for subscription of a total of 93,589,862 new ordinary shares, corresponding to an exercise rate of approximately 38 percent. Through the exercise of TO 14, Alligator Bioscience will thus receive gross proceeds of approximately SEK 19 million, corresponding to net proceeds of approximately SEK 12 million, after deduction of issue costs and repayment in accordance with the renegotiated loan agreement with Fenja Capital II A/S (for further information about the renegotiation, please refer to the Company’s press releases dated 22 October 2025).
Through the exercise of TO 14, the number of shares in the Company increases by 93,589,862 shares, from a total of 534,516,986 shares to 628,106,848 shares, of which all outstanding shares are ordinary shares. The share capital increases by SEK 18,717,972.40, from SEK 106,903,397.20 to SEK 125,621,369.60. For existing shareholders who have not exercised any warrants, the dilution amounts to approximately 15 percent based on the number of ordinary shares in the Company after the exercise of TO 14. The total number of votes in the Company after the exercise of TO 14 amounts to 628,106,848.
Exercised TO 14 will be replaced by ordinary shares after the exercise has been registered with the Swedish Companies Registration Office.
Advisers
Vator Securities AB acts as Sole Global Coordinator and bookrunner in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Alligator Bioscience in connection with the Rights Issue. Nordic Issuing AB acts as the issuing agent in connection with the exercise of TO 14.